RecruitingNCT05961865

Change in Inflammatory State in Patients Undergoing Transcatheter Ablation of Atrial Fibrillation


Sponsor

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Enrollment

180 participants

Start Date

Jul 11, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

It is a non-pharmacological (biological), spontaneous observational study. The main objective is to evaluate the correlation between inflammation markers and local adiposity, clinical risk factors and their possible variation following an AF ablation procedure


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how a catheter ablation procedure (a treatment that uses heat or cold energy to correct irregular heart rhythms) affects inflammation in the body for people with atrial fibrillation (AFib), which is an irregular heartbeat. **You may be eligible if...** - You have paroxysmal (comes and goes) or persistent AFib - You are scheduled for an approved catheter ablation procedure - You are between 18 and 85 years old - You can give informed consent **You may NOT be eligible if...** - You are older than 85 or younger than 18 - You have a blood clot in your heart's left atrial appendage - You have severe heart failure (NYHA class IV) or a very low heart pumping function (ejection fraction below 30%) - You had a heart attack, unstable chest pain, or bypass surgery in the last 6 months - You have serious conditions like cancer, kidney failure requiring dialysis, severe lung disease, or liver cirrhosis with less than 12 months life expectancy - You cannot give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMarkers of inflammation and fibrosis

Will be analyzed the following inflammation markers: Interleukin 6, N-terminal propeptide of type 1 procollagen (P1NP), chitinase-3-like protein 1 (YKL-40), tumor necrosis factor (TNF-alpha), GlycA, proprotein convertase subtilisin/kexin type 9 and omega-3 fatty acids.


Locations(1)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05961865


Related Trials